Salah Sherif* , Mubarki Abdula, Fahmy Walid, Ghaleb Heider, and Hamed Ehab
The emergence of severe acute respiratory syndrome coronavirus (SARS-CoV) in 2003 and Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in late 2012. We need to develop a universal vaccine able to boost immunity to track the coronavirus if some modifications in its structure have occurred by itself, this is what we are dealing nowadays with a virus capable of mutating its structure, while the immunity is standing still paralyzed facing the virus. Here, we report the preclinical trials of (CRCx 3) and (CRCx 2) vaccine candidate in inducing a high level of positive neutralizing antibodies as well as a cellular immune response in animal model to provide protection against SARS-CoV-2. three-dose immunizations using 0.25 ml of (CRCx) vaccines with a 25 mm needle I/M for three successive injection/7 days interval provided highly efficient protection against SARS-CoV-2. In addition, (CRCx) vaccines candidate exhibits efficient productivity and good genetic stability for vaccine manufacture. These results support the further evaluation of (CRCx) in a clinical trial.
English 
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Telugu